CTRI/2017/11/010518已完成4 期
An Open-Label, placebo controlled Study to Evaluate the Efficacy and Safety of Atosiban 6.75 mg/0.9ml in Preterm Labor
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Women =18 years of age
- •Gestational age from 24 until 33 completed weeks which has been documented by a definite LMP or sonography in the first trimester
- •Women with preterm labor.
- •The diagnosis of preterm labor requires the presence of uterine contractions with or without cervical changes
排除标准
- •Women with any of the following:
- •Chorioamnionitis
- •Preterm rupture of membranes
- •Vaginal bleeding
- •Eclampsia and severe pre-eclampsia requiring delivery
- •Intrauterine growth restriction
- •Intrauterine fetal death
- •Congenital or acquired uterine malformation
- •Severe placental insufficiency
- •Placenta previa and abruptio placentae
- •Fetal distress
- •Women who are otherwise judged inappropriate for inclusion in the study by the investigator.
研究者
相似试验
已完成
不适用
A randomised open label placebo study to evaluate the use of Solcogyn applied topically to the cervix in women referred for the assessment of cervical low grade intro-epithelial lesionsISRCTN06133220Department of Health (UK)106
已完成
4 期
To determine the clinical effectiveness and safety of a local application of Inj Reptilase in patients with bleeding of respiratory and upper digestive tractCTRI/2008/091/000208Troikaa Pharmaceuticals Limited60
招募中
2 期
An open-label, randomized controlled study evaluating the effectiveness of Pramipexole extended-release tablets for tardive dystonia patientsTardive dystoniaDrug-induced extrapyramidal syndromeG240JPRN-jRCTs031180316Iyo Masaomi24
招募中
2 期
An open-label, randomized controlled study evaluating the effectiveness of pramipexole extended-release tablets for tardive dystonia.Tardive dystoniaJPRN-UMIN000014988Department of Psychiatry, Chiba University Graduate School of Medicine24
进行中（未招募）
4 期
To study the effect of Probiotics Bacillus subtilis on Diarrhoea due to antibioticsCTRI/2018/01/011186Synergia Life Sciences Pvt Ltd